Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide.
about
Nanostructured lipid carriers: An emerging platform for improving oral bioavailability of lipophilic drugsNanotechnology-based drug delivery systems for treatment of oral cancer: a reviewPreparation and characterization of fenofibrate-loaded nanostructured lipid carriers for oral bioavailability enhancementSynthesis of CaCO3 Nanobelts for Drug Delivery in Cancer TherapyImproved pharmacokinetics and antihyperlipidemic efficacy of rosuvastatin-loaded nanostructured lipid carriers.Oral treatment with etoposide in small cell lung cancer - dilemmas and solutions.Nanostructured lipid carriers: versatile oral delivery vehicle.Advances in P-glycoprotein-based approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevance.Pharmaceutical and pharmacological approaches for bioavailability enhancement of etoposide.Nanostructured lipid carriers and their current application in targeted drug delivery.Nanodrug delivery in reversing multidrug resistance in cancer cells.Immunosuppressive drug therapy--biopharmaceutical challenges and remedies.Advances in lipid-based drug delivery: enhancing efficiency for hydrophobic drugs.Hyaluronic acid-coated cationic nanostructured lipid carriers for oral vincristine sulfate delivery.Co-delivery of etoposide and curcumin by lipid nanoparticulate drug delivery system for the treatment of gastric tumors.Targeted delivery of etoposide to cancer cells by folate-modified nanostructured lipid drug delivery system.Co-delivery of baicalein and doxorubicin by hyaluronic acid decorated nanostructured lipid carriers for breast cancer therapy.Etoposide encapsulation in surface-modified poly(lactide-co-glycolide) nanoparticles strongly enhances glioma antitumor efficiency.Etoposide-loaded immunoliposomes as active targeting agents for GD2-positive malignanciesDevelopment and optimization of sulforaphane-loaded nanostructured lipid carriers by the Box-Behnken design for improved oral efficacy against cancer: in vitro, ex vivo and in vivo assessments.Novel PEG-grafted nanostructured lipid carrier for systematic delivery of a poorly soluble anti-leukemia agent Tamibarotene: characterization and evaluation.Encapsulation of podophyllotoxin and etoposide in biodegradable poly-D,L-lactide nanoparticles improved their anticancer activity.Chlorogenic acid stabilized nanostructured lipid carriers (NLC) of atorvastatin: formulation, design and in vivo evaluation.
P2860
Q26774831-063653E5-0068-4B86-BED9-AE95A4F8BA05Q26995835-99E1F3E0-A61E-4C70-9834-17AAF38F4A0AQ30406598-78DA4D1B-9C97-411B-98EA-4DFEF0F0AFBCQ35657415-51557689-A625-41EA-AF69-D5A636BD682FQ36019637-35E2D019-DE22-418D-B461-AED32721893BQ36613874-C24F3B9A-9CAF-49DC-A0F9-5BBD9ED80338Q37474497-FF50A188-8DFF-4CA1-9B9A-9D0BCF6B064FQ38167822-B9E45E8D-DD39-42A4-A075-6F6D219C359FQ38185496-9AB9E573-151A-4739-B78F-3C5B741CE305Q38210565-72FD315D-4EEC-4B97-98C0-F371106B29A9Q38234908-A757BBC4-EE9C-49A5-AFAA-4C5265FEC739Q38340831-CFD2DB72-5468-4EF6-8C34-66AF6CD42E71Q38406190-B5942701-E948-4241-8408-B1F2FED88263Q38723241-BA107470-6EAE-4644-B44C-38914563EE19Q38740621-DBE8622D-D3AE-4D37-9FC3-A63CB3285B81Q38794049-2834D740-3524-4857-A70C-D18407B5A929Q38887061-9C194F67-3A6A-4CBE-AB77-B9F912ACE41FQ39259254-8BABDD8A-5C6B-42BB-A58C-8E87222FBE71Q42737898-83F09571-08D3-4594-BE82-C00113D288A5Q49571619-3173F042-4979-493B-8C77-B44CA4FF1271Q51109699-84999261-F7A6-436A-8F3D-8E5216CD509CQ51751638-0067926F-0950-40C8-B407-94092B4572D1Q53490135-F657936D-5969-401B-A199-82CDAFCE1C24
P2860
Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Characterization and evaluatio ...... or oral delivery of etoposide.
@en
Characterization and evaluatio ...... or oral delivery of etoposide.
@nl
type
label
Characterization and evaluatio ...... or oral delivery of etoposide.
@en
Characterization and evaluatio ...... or oral delivery of etoposide.
@nl
prefLabel
Characterization and evaluatio ...... or oral delivery of etoposide.
@en
Characterization and evaluatio ...... or oral delivery of etoposide.
@nl
P2093
P1476
Characterization and evaluatio ...... or oral delivery of etoposide.
@en
P2093
Jianian Chen
Tiecheng Zhang
Weisan Pan
P304
P356
10.1016/J.EJPS.2011.04.005
P407
P577
2011-04-20T00:00:00Z